Internet

Solid, Inc. Secures 17.7 Billion Won in 5G Equipment Orders in North America

Boldin Networks to Supply DAS for Major Infrastructure Project 6% of last year's revenue

Kim Hyun-ah
2026-10-28 07:27:55
[Edaily Reporter Kim Hyun-ah ] Telecommunications equipment company Solid, Inc.(050890)has secured a 5G equipment supply contract worth 17.7 billion won in the large-scale North American infrastructure market.

Solid, Inc. announced on the 28th that, through its U.S. subsidiary SOLiD GEAR, it received a purchase order (PO) worth approximately $13.4 million (about 17.7 billion won) from Boldyn Networks, a global telecommunications infrastructure company. This amount represents about 6% of the company’s consolidated revenue from the previous year.



The equipment to be supplied is a distributed antenna system (DAS). This equipment delivers mobile communication signals to areas where radio waves have difficulty reaching, such as buildings or subways, and will be used in this project to build 5G networks at large infrastructure facilities across the United States.

Boldin Networks is a neutral network operator that builds and operates telecommunications infrastructure for transportation facilities, stadiums, and corporate facilities in North America and Europe. It supports telecommunications carriers by enabling them to share a single infrastructure.

Solid, Inc. has been supplying DAS equipment in partnership with Boldin Networks to the New York City Subway and the London Underground, among others. It remains to be seen whether this contract win will allow the company to build on its existing partnership and secure additional business opportunities in the North American market for large-scale public and corporate facilities.

Economy

Corporation

IT·Science

Economy

SamsungElectronics Ranks First in 14 Categories of Quality Satisfaction Index… Most Categories for 18 Consecutive Years

SamsungElectronics took first place in 14 categories in the “2026 Korea Quality Satisfaction Index (KS-QEI)” evaluation organized by the Korean Standards Association, marking its 18th consecutive year…
2026-10-28 08:18:41

Corporation

Professor Yoon Jae-ho of Seoul St. Mary’s Hospital: “Anbalcel Confirms Efficacy in ALL… Sustaining That Efficacy Is the Key” [Expert Insight]

“Anvalcel demonstrated excellent safety without any fatal side effects in its Phase 1 trial for adult leukemia. Patients receiving the optimal dose showed initial treatment responses and minimal resid…
2026-10-28 07:31:02

IT·Science

'Enhertu' Approved in Europe for Early-Stage Breast Cancer… Will the Value of Alteogen Inc.'s SC Technology Rise?

Alteogen Inc.(196170)The antibody-drug conjugate (ADC) anticancer drug “Enhertu,” for which Alteogen Inc. provided subcutaneous (SC) formulation conversion technology, has been approved in Europe as a…
2026-10-28 08:18:02